8-K
filed November 9, 2023, 6:59 PM ET
ticker XTNT
CIK 0001453593
earnings
confidence high
sentiment positive
materiality 0.80
Xtant Medical reports record Q3 revenue of $25M, raises FY2023 guidance to $88M-$91M
Xtant Medical Holdings, Inc.
2023-Q3 EPS reported
$0.04
revenue$63,195,000
- Revenue $25.0M, +73% YoY; organic growth 18%; acquisition contributions 55%.
- Net income $9.2M ($0.07 EPS) vs net loss $2.4M ($0.03 loss) in Q3 2022.
- Non-GAAP adjusted EBITDA $0.5M, improved from -$0.9M in prior-year period.
- Gross margin expanded to 61.3% from 54.6% on production efficiencies and product mix.
- FY2023 revenue guidance raised to $88M-$91M from prior $75M-$77M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $25.0 million, net income $9.2 million, or $0.07 per share, EPS $0.07 per share. Guidance raised.
- Period
- third quarter ended September 30, 2023
- Revenue
- $25.0 million
- Net income
- $9.2 million, or $0.07 per share
- EPS
- $0.07 per share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xtant Medical Holdings, Inc. updated its full year 2023 guidance (raised).
- Period
- full year 2023
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Xtant Medical raises its expectation for full year 2023 revenue to $88 million to $91 million, up from the Company’s prior guidance of $75 million to $77 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.